Buy Charles River Labs
Charles River Labs (NYSE: CRL) is a contract research company that does drug discovery, safety and efficacy trials for drug companies and biotechs. While they have made many smaller acquisitions over the past few years, the Jan. 7 acquisition of WIL Research, for $585 million, will increase earnings dramatically
It gives the company a needed presence in Europe and exposure to smaller customers and new segments such as agriculture and industrial chemical testing (think bio-seeds and fertilizer safety).
We’ll have a full report in Tuesday’s issue of Profit Catalyst.
Buy CRL up to $80.